And when the long-awaited trial does finally report it will have to be a smash hit.
After the Valor defeat, the group and its partner Biogen will hope that going earlier could improve the amyotrophic lateral sclerosis project’s chances.
The group’s Covid-19 vaccine is on course for UK approval – but the UK doesn’t want it.
Astrazeneca’s Himalaya study is a surprising hit in first-line liver cancer, but competition is already present.
But questions about gene therapy safety could benefit the enzyme-replacement therapy incumbents.
Molnupiravir, a repurposed flu antiviral with a poor history, delivers in a pivotal study in Covid-19 outpatients.
But another safety scare for the big pharma’s Duchenne muscular dystrophy project could be good news for Sarepta.